autologous TIL 1383I-expressing T-cell therapy (Loyola University)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameautologous TIL 1383I-expressing T-cell therapy (Loyola University)
Drug Alias Nameanti-tyrosinase/HLA-A2 TCR T-cell therapy (Loyola University)autologous TIL 1383I TCR-expressing CD4+/CD8+ T-cell therapy (Loyola University)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulatorsTyrosinase modulators
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha ChainTyrosinase
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLoyola University
China Registration ClassN/A

Develop Information

Active CompaniesLoyola University
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A